Overview

• National reference labs detected initial XFG cases in epidemiological weeks 26–27 and report that the variant now represents more than 50% of samples in weeks 25–28
• The World Health Organization classifies XFG as a Variant Under Monitoring after confirming it as a recombinant of Omicron sublineages LF.7 and LP.8.1.2 with low additional risk
• Global prevalence of XFG rose from 7.4% to 22.7% of sequenced samples between weeks 19–22 and reached 49% by mid-July across at least 38 countries
• Clinical reports link XFG infections to hoarseness, aphonia and temporary voice loss without evidence of increased severity or hospitalization rates
• Health authorities recommend booster doses every six months for high and intermediate risk groups and annual boosters for lower-risk populations to sustain protection